Shots:
- Hikma has acquired the Novugen’s US FDA ANDA approved trametinibtablets and also entered into a commercial agreement with Novugen
- Under the agreement, Hikma will be responsible for all the US sales and marketing of trametinib while Novugen will manufacture and supply them to Hikma. Furthermore, when product is launched Hikma will have 180 days of US generic market sales exclusivity for trametinib
- Trametinib is an orally administered kinase inhibitor medication used to treat melanoma and glioma
Ref: Hikma | Image: Hikma
Related News:- Sanofi Enters a ~$1.84B Global License Agreement with Earendil Labs for HXN-1002 & HXN-1003
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
